3.39

2.87% -0.10

Niagen Bioscience Inc (NAGE)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$3.49

Offen:

$3.48

24-Stunden-Volumen:

387.41K

Relative Volume:

0.47

Marktkapitalisierung:

$269.99M

Einnahmen:

$130.42M

Nettoeinkommen (Verlust:

$18.64M

KGV:

15.54

EPS:

0.2182

Netto-Cashflow:

$4.05M

1W Leistung:

-1.17%

1M Leistung:

-2.31%

6M Leistung:

-48.01%

1J Leistung:

-71.25%

1-Tages-Spanne:

$3.39

$3.51

1-Wochen-Bereich:

$3.33

$3.64

52-Wochen-Spanne:

$3.175

$11.90

Niagen Bioscience Inc Stock (NAGE) Company Profile

Firmenname

Niagen Bioscience Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

310-388-6706

Adresse

10900 WILSHIRE BLVD, LOS ANGELES

Mitarbeiter

117

Twitter

Nächster Verdiensttermin

2026-08-05

Neueste SEC-Einreichungen

NAGE's Discussions on Twitter

Compare NAGE vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NAGE Niagen Bioscience Inc	3.39	269.99M	130.42M	18.64M	4.05M	0.2182
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-27	Eingeleitet	Canaccord Genuity	Buy
2022-08-16	Herabstufung	Oppenheimer	Outperform → Perform
2022-08-11	Herabstufung	B. Riley Securities	Buy → Neutral
2022-03-08	Eingeleitet	ROTH Capital	Buy
2019-10-16	Eingeleitet	Oppenheimer	Outperform
2019-02-14	Eingeleitet	B. Riley FBR	Buy
2017-11-27	Fortgesetzt	H.C. Wainwright	Buy
2017-09-25	Eingeleitet	Ladenburg Thalmann	Buy
2017-01-03	Eingeleitet	Rodman & Renshaw	Buy

Alle ansehen

Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten

Jul 11, 2026

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science - AOL.com

Jul 11, 2026

Jul 10, 2026

Niagen Bioscience files prospectus to offer common stock up to $50M - scanx.trade

Jul 10, 2026

Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com - Investing.com South Africa

Jul 10, 2026

Canaccord reiterates Niagen Bioscience stock rating on drug launch By Investing.com - Investing.com Canada

Jul 10, 2026

Jul 09, 2026

Fed. Circ. Doubts $9M Atty Fees Without Dismissal Attempt - Law360

Jul 09, 2026

Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital - MarketBeat

Jul 09, 2026

Niagen Bioscience unveils NB-4168 for ataxia telangiectasia - BioWorld News

Jul 09, 2026

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026 - Business Wire

Jul 09, 2026

Jul 08, 2026

Form 4 Niagen Bioscience Inc For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan - Stock Titan

Jul 08, 2026

Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases - marketscreener.com

Jul 08, 2026

Niagen Bioscience launches drug candidate for rare disease - Investing.com

Jul 08, 2026

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases - Business Wire

Jul 08, 2026

Jul 06, 2026

Enterprise value to EBIT forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView

Jul 06, 2026

Freedom Capital Markets Initiates Niagen Bioscience(NAGE.US) With Buy Rating, Announces Target Price $9 - Moomoo

Jul 06, 2026

Freedom Broker initiates Niagen Bioscience stock coverage with buy rating By Investing.com - Investing.com Nigeria

Jul 06, 2026

Freedom Broker initiates Niagen Bioscience stock coverage with buy rating - Investing.com

Jul 06, 2026

Implied Volatility Surging for Niagen Bioscience Stock Options - Zacks Investment Research

Jul 06, 2026

Jul 04, 2026

NAGENiagen Bioscience Inc Options - Finviz

Jul 04, 2026

Jul 01, 2026

H.C. Wainwright reiterates Niagen Bioscience stock rating on patent ruling By Investing.com - Investing.com India

Jul 01, 2026

Jun 29, 2026

Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com - Investing.com Australia

Jun 29, 2026

Jun 26, 2026

Form 4 Niagen Bioscience Inc For: 26 June By Investing.com - Investing.com South Africa

Jun 26, 2026

Niagen Bioscience (NAGE) director receives 31,746 stock options at $3.45 strike - Stock Titan

Jun 26, 2026

Niagen Bioscience (NAGE) director awarded options for 31,746 shares at $3.45 strike - Stock Titan

Jun 26, 2026

Director at Niagen Bioscience (NAGE) receives 31,746 stock options award - Stock Titan

Jun 26, 2026

Niagen Bioscience (NAGE) director granted 31,746 stock options at $3.45 - Stock Titan

Jun 26, 2026

Niagen Bioscience (NAGE) director receives 31,746-share stock option grant at $3.45 - Stock Titan

Jun 26, 2026

Director Steven D. Rubin receives 31,746 Niagen Bioscience (NAGE) stock options - Stock Titan

Jun 26, 2026

Niagen Bioscience (NAGE) director receives grant of 31,746 stock options at $3.45 - Stock Titan

Jun 26, 2026

Jun 25, 2026